January 30, 2020
Alexion Pharmaceuticals announced its financial results for the fourth quarter and its full fiscal 2019 year.
January 14, 2020
Alexion announced that is plans to start a Phase 3 study of ULTOMIRIS (ravulizumab) in amyotrophic lateral sclerosis (ALS).
December 4, 2019
2019 is at an end, which means it's time to reflect on the top-performing NASDAQ pharma stocks year-to-date.
March 26, 2019
A report by Cortellis says that seven drugs entering the market in 2019 are projected to reach blockbuster status by...
September 24, 2018
Alexion Pharmaceuticals (NASDAQ:ALXN) today announced positive topline results from the Phase 3 PREVENT study of Soliris (eculizumab) in patients with anti-aquaporin-4 (AQP4)...
June 28, 2018
Alexion Pharmaceuticals (NASDAQ:ALXN) announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for ALXN1210, the...